Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Early Phase 1
2(66.7%)
Phase 4
1(33.3%)
3Total
Early Phase 1(2)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT03288805Active Not Recruiting

Cohort Study in South China

Role: collaborator

NCT05277987Early Phase 1Unknown

An Evaluation Trial About Anti-claudin18.2 the Specificity of Chimeric Antigen Receptor T Cells in the Advanced Gastric / Esophagogastric Junction Adenocarcinoma and Pancreatic Cancer Subjects

Role: lead

NCT03662477Early Phase 1Unknown

Effect of NK Cell Immunotherapy on Advanced Lung Adenocarcinoma Adenocarcinoma With EGFR Mutation

Role: lead

NCT03777930Phase 4Unknown

The Evaluation of Curative Effect on Treatment of Tumor Above Thalidomide Combined With Megestrol

Role: lead

All 4 trials loaded